XML 49 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Unaudited Quarterly Financial Information (Tables)
12 Months Ended
Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information
The following is a summary of our unaudited quarterly results for the years ended December 31, 2013 and 2012:
 
 
Quarter Ended
2013 (Unaudited):
 
March 31,
 
June 30,
 
September 30,
 
December 31,
Total revenues
 
$
11,833,540

 
$
14,453,810

 
$
16,013,164

 
$
12,498,933

Gross profit on product sales(1)
 
$
769,623

 
$
1,815,903

 
$
9,342,187

 
$
6,266,250

Total operating expenses
 
$
30,329,313

 
$
36,574,458

 
$
34,507,020

 
$
33,822,293

Net loss
 
$
(19,288,369
)
 
$
(22,911,511
)
 
$
(19,292,368
)
 
$
(21,986,303
)
Net loss per share, basic and diluted
 
$
(0.17
)
 
$
(0.20
)
 
$
(0.17
)
 
$
(0.19
)
Shares used in computing basic and diluted net loss
per share
 
112,416,792

 
112,486,211

 
112,765,155

 
113,550,229

 
 
 
 
 
 
 
 
 
 
 
Quarter Ended
2012 (Unaudited):
 
March 31,
 
June 30,
 
September 30,
 
December 31,
Total revenues(2)
 
$
7,440,179

 
$
7,757,175

 
$
5,334,323

 
$
21,793,549

Gross profit on product sales
 
$
116,650

 
$
381,822

 
$
488,719

 
$
805,851

Total operating expenses
 
$
22,580,577

 
$
21,805,273

 
$
25,364,160

 
$
26,200,662

Net loss
 
$
(15,119,181
)
 
$
(14,021,119
)
 
$
(20,005,846
)
 
$
(4,405,856
)
Net loss per share, basic and diluted
 
$
(0.14
)
 
$
(0.13
)
 
$
(0.18
)
 
$
(0.04
)
Shares used in computing basic and diluted net loss
per share
 
107,589,514

 
112,063,665

 
112,305,002

 
112,323,056

 
 
(1)
Gross profit on product sales for the quarters ended June 30, 2013, September 30, 2013 and December 31, 2013 excluded manufacturing costs related to the product sales of bulk rHuPH20 for Herceptin SC and HyQvia in the amounts of $873,000, $6.5 million and $2.6 million, respectively. Such costs were incurred prior to European marketing approvals for Herceptin SC and HyQvia, and therefore, they were charged to research and development expenses in the periods the costs were incurred.
(2)
Revenues for the quarter ended December 31, 2012 included $9.5 million in revenues under collaborative agreements from the Pfizer Collaboration.